Soleno Therapeutics (SLNO) to Release Quarterly Earnings on Wednesday

Soleno Therapeutics (NASDAQ:SLNO - Get Free Report) is expected to issue its Q1 2025 quarterly earnings data after the market closes on Wednesday, May 7th. Analysts expect Soleno Therapeutics to post earnings of ($1.08) per share for the quarter.

Soleno Therapeutics (NASDAQ:SLNO - Get Free Report) last issued its quarterly earnings data on Wednesday, March 5th. The company reported ($1.27) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.86) by ($0.41). On average, analysts expect Soleno Therapeutics to post $-4 EPS for the current fiscal year and $-3 EPS for the next fiscal year.

Soleno Therapeutics Stock Performance

Shares of NASDAQ SLNO traded up $0.78 during mid-day trading on Monday, reaching $76.01. 221,240 shares of the company traded hands, compared to its average volume of 723,773. The company's fifty day moving average is $60.27 and its two-hundred day moving average is $53.60. Soleno Therapeutics has a fifty-two week low of $36.93 and a fifty-two week high of $76.56. The stock has a market cap of $3.79 billion, a PE ratio of -22.89 and a beta of -2.67.

Insider Activity

In other news, CFO James H. Mackaness sold 90,622 shares of the company's stock in a transaction dated Thursday, March 27th. The stock was sold at an average price of $69.44, for a total transaction of $6,292,791.68. Following the completion of the transaction, the chief financial officer now directly owns 105,176 shares of the company's stock, valued at $7,303,421.44. This represents a 46.28 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, CEO Bhatnagar Anish sold 699,095 shares of Soleno Therapeutics stock in a transaction that occurred on Thursday, March 27th. The shares were sold at an average price of $67.62, for a total transaction of $47,272,803.90. Following the completion of the sale, the chief executive officer now owns 577,076 shares in the company, valued at $39,021,879.12. This trade represents a 54.78 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last quarter, insiders have sold 942,672 shares of company stock valued at $64,058,781. 12.30% of the stock is currently owned by insiders.

Analyst Ratings Changes

A number of equities research analysts have issued reports on SLNO shares. Piper Sandler upped their price target on shares of Soleno Therapeutics from $93.00 to $145.00 and gave the company an "overweight" rating in a report on Thursday, April 24th. Stifel Nicolaus lifted their price objective on Soleno Therapeutics from $74.00 to $108.00 and gave the stock a "buy" rating in a report on Friday, March 28th. UBS Group set a $105.00 target price on shares of Soleno Therapeutics in a report on Thursday, March 27th. Guggenheim reaffirmed a "buy" rating and set a $81.00 price target (up from $70.00) on shares of Soleno Therapeutics in a report on Friday, March 28th. Finally, Robert W. Baird boosted their price objective on Soleno Therapeutics from $72.00 to $102.00 and gave the stock an "outperform" rating in a research note on Thursday, March 27th. Eight investment analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the stock. According to MarketBeat, the stock presently has a consensus rating of "Buy" and an average target price of $104.67.

Soleno Therapeutics Company Profile

Soleno Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for the treatment of rare diseases. Its lead candidate is Diazoxide Choline Extended-Release tablets, a once-daily oral tablet, which is in Phase III clinical trials for the treatment of Prader-Willi Syndrome.